Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Simonson PD, Valencia I, Patel SS. Tyramide-conjugated DNA barcodes enable signal amplification for multiparametric CODEX imaging. Commun Biol. 2022;5(1):627.

Marchionni L, Lobo FP, Kostadinov R, Serra A, Besso FG, Deaglio S, et al. Donor-derived acute myeloid leukemia in solid organ transplantation. Am J Transplant. 2022;22(12):3111-3119.

Charpentier M, Spada S, Van Nest SJ, Demaria S. Radiation therapy-induced remodeling of the tumor immune microenvironment. Semin Cancer Biol. 2022;86(Pt 2):737-747.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Liu C, Zhou N, Levitan D, Guzman JC, Fehniger J. Cutaneous metastasis of PD-L1 positive cervical carcinoma. Gynecol Oncol Rep. 2022;41:101003.

Papke DJ, Lindeman NI, Schrag D, J Iorgulescu B. Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1746-1751.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Guerrero-Preston R, Rivera-Amill V, Caraballo K, Rodriguez-Torres S, Purcell-Wiltz A, García AA, et al. Precision health diagnostic and surveillance network uses S gene target failure (SGTF) combined with sequencing technologies to track emerging SARS-CoV-2 variants. Immun Inflamm Dis. 2022;10(6):e634.

Demaria S. Something Old and Something New to Unleash the Power of Natural Killer Cells against Metastases. Cancer Immunol Res. 2022;10(1):3.

2021

Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials. 2021;22(1):323.